Guerra Veloz, María FernandaCordero Ruiz, PatriciaRíos-Villegas, María JoséDel Pino Bellido, PilarBravo-Ferrer, JoséGalvés Cordero, RocíoCadena Herrera, María LorenaVías Parrado, CarmenBellido Muñoz, FranciscoVega Rodríguez, FranciscoCaunedo Álvarez, ÁngelRodríguez-Baño, JesúsCarmona Soria, Isabel2022-08-262022-08-262021Guerra Veloz MF, Cordero Ruiz P, Ríos-Villegas MJ, Del Pino Bellido P, Bravo-Ferrer J, Galvés Cordero R, et al. Liver manifestations in COVID-19 and the influence of pre-existing liver disease in the course of the infection. Rev Esp Enferm Dig. 2021 Feb;113(2):103-1091130-0108http://hdl.handle.net/10668/3957Introduction: patients with advanced chronic liver disease (CLD) may be at an increased risk of a severe course due to cirrhosis-associated immune dysfunction. The aim of this study was to determine the prevalence of CLD in COVID-19 patients and to analyze the course of the infection, com pared with patients with non-liver disease. Materials and methods: this was a retrospective single cen ter study of all patients with a positive SARS-CoV-2 poly merase chain reaction (PCR) test from March 23rd to April 30th, 2020. Clinical and biochemical data of patients with and without CLD and COVID-19 were collected from the medical records. Result: four hundred and forty-seven patients with a SARS CoV-2 positive PCR were included, 6.3 % had CLD; 69.7 % of patients with CLD were male, with a median age of 65.5 years and active alcohol consumption and smoking; 75 % had non-advanced liver fibrosis and most had non-alcoholic fatty liver disease (NAFLD). The hospital admission rate (92.9 % vs 47.7 %, p < 0.001), concomitant comorbidities (diabetes 38.5 vs 16.5 %, p = 0.011; obesity 30.8 vs 8.5 %, p = 0.033; cancer 23.1 vs 5 %, p = 0.027; and chronic obstructive pulmonary disease (COPD) 19.2 vs 9 %, p = 0.009) and con comitant antibiotics treatment (19.3 vs 5 %, p = 0.018) were higher in patients with CLD than in those without CLD. In patient hospital mortality rates were similar in both groups (30.8 vs 19.6 %, p = 0.289). The presence of CLD was not associated with mortality (OR = 1.06; 95 % CI = 0.35-3.18; p = 0.924). However, patients with CLD and COVID-19 who were male, obese or under concomitant antibiotic treat ment had the highest risk of mortality according to the uni variate analysis. Conclusion: patients with CLD had a higher risk of hospi tal admission, with worse outcomes during the COVID-19 infection associated to other concomitant comorbidities and a suspicion of bacterial co-infection.enAtribución-NoComercial 4.0 Internacionalhttp://creativecommons.org/licenses/by-nc/4.0/SARS-CoV-2Chronic liver diseaseAdvanced fibrosisHospital admission rateMortalityHepatopatía terminalFibrosisPruebas de admisón rutinariasMortalidadMedical Subject Headings::Persons::Persons::Age Groups::Adult::AgedMedical Subject Headings::Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic DiseaseMedical Subject Headings::Check Tags::FemaleMedical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::HumansMedical Subject Headings::Diseases::Digestive System Diseases::Liver DiseasesMedical Subject Headings::Check Tags::MaleMedical Subject Headings::Persons::Persons::Age Groups::Adult::Middle AgedMedical Subject Headings::Information Science::Information Science::Data Collection::Vital Statistics::Morbidity::PrevalenceMedical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies::Retrospective StudiesMedical Subject Headings::Organisms::Viruses::RNA Viruses::Nidovirales::Coronaviridae::Coronavirus::SARS Virusresearch article33393329open access10.17235/reed.2020.7627/2020340-4167